发明申请
WO2009032845A3 POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS
审中-公开
基本信息:
- 专利标题： POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS
- 专利标题（中）：多肽和多核苷酸及其用作生产药物和生物制品的药物目标
- 申请号：PCT/US2008075122 申请日：2008-09-03
- 公开(公告)号：WO2009032845A3 公开(公告)日：2009-05-28
- 发明人： LEVINE ZURIT , ROSENBERG AVI , ROTMAN GALIT , NOVIK AMIT , TOPORIK AMIR , KINAR YARON , NEMZER SERGEY , KOIFMAN CYNTHIA , BEIMAN MERAV , DASSA LIAT , WALACH SHIRA , MONTIA EVE , SAMEACH-GREENWALD SHIRLEY , PERGAM TANIA , MILO DALIT , COHEN-DAYAG ANAT , LEVY OFER , BUBIS MARINA
- 申请人： COPUGEN LTD , COMPUGEN USA INC , LEVINE ZURIT , ROSENBERG AVI , ROTMAN GALIT , NOVIK AMIT , TOPORIK AMIR , KINAR YARON , NEMZER SERGEY , KOIFMAN CYNTHIA , BEIMAN MERAV , DASSA LIAT , WALACH SHIRA , MONTIA EVE , SAMEACH-GREENWALD SHIRLEY , PERGAM TANIA , MILO DALIT , COHEN-DAYAG ANAT , LEVY OFER , BUBIS MARINA
- 专利权人： COPUGEN LTD,COMPUGEN USA INC,LEVINE ZURIT,ROSENBERG AVI,ROTMAN GALIT,NOVIK AMIT,TOPORIK AMIR,KINAR YARON,NEMZER SERGEY,KOIFMAN CYNTHIA,BEIMAN MERAV,DASSA LIAT,WALACH SHIRA,MONTIA EVE,SAMEACH-GREENWALD SHIRLEY,PERGAM TANIA,MILO DALIT,COHEN-DAYAG ANAT,LEVY OFER,BUBIS MARINA
- 当前专利权人： COPUGEN LTD,COMPUGEN USA INC,LEVINE ZURIT,ROSENBERG AVI,ROTMAN GALIT,NOVIK AMIT,TOPORIK AMIR,KINAR YARON,NEMZER SERGEY,KOIFMAN CYNTHIA,BEIMAN MERAV,DASSA LIAT,WALACH SHIRA,MONTIA EVE,SAMEACH-GREENWALD SHIRLEY,PERGAM TANIA,MILO DALIT,COHEN-DAYAG ANAT,LEVY OFER,BUBIS MARINA
- 优先权： US96986507 2007-09-04; US96979907 2007-09-04; US96978007 2007-09-04; US96980607 2007-09-04; US96976907 2007-09-04; US96978807 2007-09-04
- 主分类号： A61K39/00
- IPC分类号： A61K39/00
摘要：
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
摘要（中）：
本发明涉及用于生产基于免疫和非免疫的治疗剂和用于疾病诊断的新型靶。 更具体地说，本发明提供了针对VSIG1，ILDR1，LOC253012，AI216611，C1ORF32或FXYD3抗原的治疗性抗体，其是预测的共刺激家族成员并且在癌症包括肺癌，卵巢癌和结肠癌中差异表达，以及 诊断和治疗用法。 还提供了这些抗体用于调节B7共刺激和相关疗法如治疗自身免疫的用途。 本发明进一步涉及VSIG1及其变体，FXYD3及其变体，ILDR1及其变体，LOC253012及其变体，AI216611及其变体，以及C1ORF32及其变体的细胞外结构域的发现，它们是免疫治疗，癌症治疗 和药物开发。
IPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K39/00 | 含有抗原或抗体的医药配制品 |